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Abstract
Background: Endostar is a new endogenous angiogenic inhibitor with implicated anti-tumor activity. This study
was to investigate whether thoracic perfusion of Endostar could be used to control malignant pleural effusions
(MPE).
Methods: We searched the databases of MEDLINE, Web of Science, EMBASE, Goggle, Cochrance Library and CNKI
to select the studies regarding the efficacy of Endostar to treat MPE. A total of 13 randomised controlled trials
(RCTs) with 1066 patients were included.
Results: The overall response rate (ORR) (P < 0.001; odds ratio = 3.58) and disease control rate (DCR) (P < 0.001; odds
ratio = 2.97) of Endostar combined with chemotherapeutic agents were significantly higher than those of
chemotherapeutic agents alone. In addition, Endostar combined treatment remarkably promoted quality of life
(QOL) of patients (P < 0.001; odds ratio = 3.04) compared with that of chemotherapeutic agents alone. Moreover,
Endostar combined treatment did not have an impact on the incidence of adverse reactions (AEs) (P < 0.05).
Conclusions: The efficacy of Endostar combined chemotherapeutic agents was superior to chemotherapeutic
agents alone through thoracic perfusion in treating MPE, which indicated that Endostar could be an effective agent
for controlling MPE.
Keywords: Endostar, Malignant pleural effusions, MPE, Meta-analysis, Efficacy, Safety
Background
In China, lung cancer has been becoming a major cause
of death in malignant tumors due to increasingly air pol-
lution and deterioration of the natural environment. In
2015 in China, There is dreadful fact that 733,000 lung
cancer cases were diagnosed and 610,000 patients will
die from this disease [1]. In clinic, most of lung cancer
patients always are accompanied with the event of
malignant pleural effusions (MPE), which leads to a
lower quality of life and even reduced the life expect-
ancy. Thus, doctors often pay more attention to the
treating of MPE and the prolongation of survival [2].
Traditional treatments of MPE include drainage of
pleural effusion, pleural adhesions and pharmacotherapy
and so on. In addition, thoracic perfusion of chemother-
apeutic agents has been suggested to be used in control-
ling of the effusion. The main opinion is that the
intrapleural levels of a chemotherapy agent administered
into the pleural space can be significantly higher than
the systemic levels [3]. However, most of lung cancer
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cases are often resistant to standard chemotherapy
agent, or eventually become chemoresistant. Therefore,
the fact is many chemotherapeutic agents are not as ef-
fective as we expected in treating MPE via thoracic per-
fusion [4]. Today, novel molecular targeted drugs that
have been studied to improve the cure and control rate
of the disease. Because of strong antineoplastic activity
and low toxicity, these products have been used as alter-
native treatments for the control of MPE [5].
Endostatin is a naturally-occurring, 20-kDa C-terminal
fragment derived from type XVIII collagen, which was
first reported by Folkman. Endostatin has been reported
to inhibit angiogenesis in a wide range of tumors, and
may interfere with the pro-angiogenic effects of growth
factors. Capillary endothelial cells are the targets of endo-
statin, endostatin blocks endothelial cell proliferation and
formation of new blood vessels, and affects the progress
and metastasis of malignant tumors [6]. A new recombin-
ant human endostatin (code number: YH-16), Endostar, is
developed by Simcere-Medgenn Bioengineering Co. Ltd,
Nanjing and Yantai, China, and is different from the ori-
ginal endostatin studied by O’Reilly [6, 7], which was ap-
proved by the China State Food and Drug Administration
(SFDA) for the treatment of non- small cell lung cancer as
the first therapy in 2005 [8]. Endostar has a structural
difference compared with endostatin reported in previous
literature, which purified in Escherichia coli with an
additional nine-amino acid sequence (MGGSHHHHH)
[9, 10]. Some studies suggested that the antiangiogenic
biological function has been promoted because of such
a structural changes on this drug in treating lung
cancer [8, 11, 12].
Recent years, some studies have specially investigated
the clinical effect and safety of Endostar combined with
chemotherapeutic agents versus chemotherapeutic agents
alone in treating MPE via thoracic perfusion. Here, we
performed a systematic literature review to assess the clin-




We searched and identified relevant randomized con-
trolled trials (RCTs) from the databases of MEDLINE/
PubMed, EMBASE, Cochrance Library, SCI, and CNKI
database (from January 2005 to April 2016). We adopted
various MeSH terms and key words that related to MPE
and Endostar as follows: “malignant pleural effusion,”
“MPE,” “rh-endostatin,” “endostatin,” “chemotherapy,”
“Endostar,” and “recombinant human endostatin injec-
tion.” In addition, if we found useful information that
was intimately associated with Endostar in the refer-
ence lists of those studies, we should further look for
additional studies and identified them.
Collection of study variables
The data that we extracted included: (1) the number of
patients of each RCT, (2) publication date of literature,
(3) the clinical characteristics of data, (4) the ways of
clinical intervention, (5) overall response (ORR) and dis-
ease control rate (DCR) and (6) quality of life (QOL)
and adverse effects (AEs).
Criteria that studies were included and excluded
Inclusion criteria: (1) studies must be designed to com-
pare Endostar plus chemotherapeutic agents to chemo-
therapeutic agents alone; (2) patients must be given
drugs through thoracic perfusion; (3) patients must be
diagnosed with MPE; (4) outcome measures must be re-
ported; and (6) the total cases of patients must be
greater than or equal to (but not less than) 50. Exclusion
criteria: (1) studying on animals not human; (2) patients
were given excessive other adjutant drugs; (3) studies
were sponsored by pharmaceutical manufacturers; and
(4) study was short of efficient control group.
Supervision of the implementation process
Trial design: RCTs of Endostar combined with chemo-
therapeutic agents versus chemotherapeutic agents alone
through thoracic perfusion for treating MPE. The ways
of interventions: the dosage was defined according to
the statement of manufacturers and frequency of admin-
istration at least 2 times; Evaluation indicators of thera-
peutic efficacy: ORR, DCR, QOL, and AEs.
Quality assessment of included RCTs
We utilized the evaluation criteria shaped by Cochrane
Handbook (Version 5.0.1) to assess the included trials,
which included: (1) methods to random group of pa-
tients; (2) how to perform an adequate setting blinding;
(3) how to perform an adequate allocation and conceal
the sequence; and (4) a description of intention to treat.
Eventually, the quality of trials was divided into three
levels: low risk of bias, unclear risk of bias, and high risk
of bias [13, 14].
Statistical methods and analysis
After sufficient data were collected and identified, the
process of meta-analysis was implemented. The odds
ratio (OR) with 95 % confidence intervals (CI) were
major statistical data that were applied to explore the
difference of efficacy. The overall effect was calculated
by Z-scores and P-values <0.05 were considered to be
statistically significant. The identification of homogen-
eity was studies was calculated by the χ2 statistic and
was quantified with the I2 statistic. In our study, we
adopted fixed effects model preferential to perform
meta-analysis. We also used meta-regression to evaluate
whether the results were different between two groups.
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In order to assess the bias of literature, we omitted each
study from the estimated pool to analyze the influence
of each study to overall effect. In addition, funnel plots,
Egger’s test, and Begg’s test were performed to assess
publication bias. We used SPSS (SPSS Institute, version
19.0, Chicago, USA) and Stata version 15.0 (Stata
Corporation, TX, USA) to implement the statistical ana-
lysis and used a significance level of P <0.05.
Results
Study selection process
Originally, 122 potentially relevant studies were identi-
fied. Of them, 66 studies were removed because they
were not original literature such as review, abstract and
meeting records. Remaining 56 studies were identified as
requiring RCTs, but 31 studies were excluded subse-
quently because of the following reasons: did not de-
scribe a clear control; did not have usable end points;
duplicate of another study; non-human studies; low
quality of statistics; and too small sample size. Of the
remaining 25 trials, 12 were excluded further because
complicated combination therapy and low design qual-
ity. Finally, 13 [15–27] studies published between 2010
and 2015 were included (Fig. 1). The eligible studies
contained a total of 1066 patients with the sizes of dis-
tributing from 56 [18] to 120 [20] patients. The cause of
MPE mainly included lung cancer (918 cases), breast
cancer (78 cases) and digestive tract tumors (56 cases).
A meta-analysis database was established according to
the extracted data, which was listed in Tables 1 and 2.
Quality of study design
The design of 8 studies were that Endostar combined with
cisplatin versus cisplatin alone through thoracic perfusion
for treating MPE [15, 16, 18, 20, 21, 23, 24, 27], 2 studies
were Endostar combined with bleomycin versus bleo-
mycin alone [17, 26], 2 studies Endostar combined with
nedaplatin versus nedaplatin alone [19, 25] and one Endo-
star combined with lobaplatin versus lobaplatin alone
[22]. The dosage of Endostar via thoracic perfusion and
follow-up times for efficacy evaluation had a good
consistency, which was shown in Table 2. Generally,
the dosage of Endostar was administered at the range
of 30–90 mg per one time and frequency of adminis-
tration was two times at least, which were dissolved in
physiological saline, and given by thoracic perfusion after
drainage of pleural effusions.
Quality of study characteristics
Two investigators independently reviewed and deter-
mined the quality of each study. The discrepancies were
resolved by consensus with the third expert. The evalu-
ation was performed according to the evaluation criteria
established by Cochrane Handbook (Version 5.0.1) [28].
As shown in Table 3, the results showed that 4 of the 13
studies (30.7 %) belonged to the low risk of bias [17, 20,
24, 27], and the rest [1, 4, 5, 8–10, 15, 16, 18, 19, 21–23,
25, 26, 29] were inclined to indicate an unclear risk of
bias (69 %) (Table 3).
Comparison of ORR
We identified 13 RCTS [15–27] pertaining to ORR
comparison. The odds ratio of fixed-effects was 3.58
(95 % CI 2.73 to 4.69; Z = 9.24, p < 0.001; Fig. 2),
which indicated that the ORR of Endostar combined
treatment was significantly higher than that of che-
motherapeutic agents alone. Among these 13 studies,
we did not observe the evidence of heterogeneity
Fig. 1 Flow chart of literature search. RCTs, randomized controlled trials
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Table 1 Data analysis of included studies
Study N Male Female Age (average) Sources of tumor (N) Volume of MPE (N) Quality of Life End point
Lung/pleura Breast Digestive tract Others
Liu W 2010 [15] 96 51 45 40–70 96 – – – Unavailable KPS RR, DCR, SI, AEs
Mao L 2011 [16] 90 45 45 27–70 81 5 2 2 >1000 ml KPS RR, DCR, SI, AEs
Li G 2011 [17] 60 30 30 41–76 25 20 15 – Large (37)
Moderate (23)
KPS RR, DCR, SI, AEs
Ma E 2012 [18] 56 32 24 35–67 56 – – – >1000 ml Unavailable RR, DCR, SI, AEs
Yao Q 2012 [19] 60 42 18 35–78 28 16 4 12 >1000 ml KPS RR, DCR, SI, AEs
Zheng Q 2013 [20] 120 73 47 32–75 78 25 17 – >1000 ml KPS RR, DCR, SI, AEs
Kang Y 2013 [21] 90 53 37 18–72 90 – – – >1000 ml KPS RR, DCR, SI, AEs
Wen J 2014 [22] 60 34 26 35–65 (50.5) 45 9 6 – Large (13)
Moderate (29)
Small (18)
KPS RR, DCR, SI, AEs
Yue G 2014 [23] 86 48 42 38–69 86 – – – Unavailable KPS RR, DCR, SI, AEs
Tu J 2014 [24] 90 41 49 45–70 90 – – – Unavailable KPS RR, DCR, SI, AEs
Xu J 2014 [25] 70 43 27 44–70 70 – – – >1000 ml KPS RR, DCR, SI, AEs
Wen X 2015 [26] 104 69 35 39–76 104 – – – Unavailable KPS RR, DCR, SI, AEs
Hu X 2015 [27] 84 62 22 18–70 69 3 12 – >1000 ml ECOG RR, DCR, SI, AEs
N number of patients, MPE malignant pleural effusion, KPS karnofsky physical status score, RR response rate, DCR disease control rate, SI symptom improvement, AEs adverse effects, ECOG Eastern Cooperative











(heterogeneity chi-squared = 8.23; p = 0.767). More-
over, sensitivity analysis revealed the odds ratio and
95 % CI did not change when we omitted anyone
study, with an odds ratio pool changing between 2.08
to 6.82.
Comparison of DCR
Eleven trials [15, 17–22, 24–27] compared the DCR.
The odds ratio of the fixed effects model ranged from
0.96 to seven and did not imply the existence of hetero-
geneity (heterogeneity chi-squared = 6.15; p = 0.803).
The pooled odds ratio was 2.97 (95 % CI 2.02 to
4.35; Z = 5.57, p < 0.001), which indicated that Endostar
combined with chemotherapeutic agents promoted the
DCR, compared with chemotherapeutic agents alone
(Fig. 3).
Comparison of QOL after treatment
Twelve studies [15–24, 26, 27] investigated the changes
of QOL after treatment. The Endostar combination arms
had a higher symptom improvement rate than chemo-
therapeutic agents alone (odds ratio = 3.04, 95 % CI 2.28
to 4.04; test for overall effect: Z = 7.64, p < 0.001) (Fig. 4).
Adverse reactions comparison of two projects
As shown in Table 4, nine studies compared the adverse
effects, which presented five common AEs including
myelotoxicity, gastrointestinal toxicity, liver and renal
function injury, arrhythmia and fever. The meta-analysis
showed that incidence of myelotoxicity [17, 19–25, 27]
were similar in Endostar combined with chemotherapeu-
tic agents and chemotherapeutic agents alone (odds
ratio = 1.14, 95 % CI 0. 83 to 1.58, p =0.423) (Fig. 5a).
The incidence of gastrointestinal toxicity in two projects
[17, 19–25, 27] did not have a significant difference
(odds ratio = 1.25, 95 % CI 0. 88 to 1.80, p =0.214)
(Fig. 5b). Five studies [17, 21, 24, 25, 27] compared liver
and renal injury, six studies compared arrhythmia [17,
21, 22, 24, 25, 27], and four studies compared fever, all
results suggested that the incidence rate of these AEs
did not have differences between both of two projects
(p > 0.05) (Fig. 6a, b and c).
Assessment of publication bias and meta-regression
analysis
The shape of Begg’s funnel plot seems to be symmetrical
(Std. Dev. of Score = 16.39, z = 0.37, Pr > z = 0.716),












Liu W 2010 [15] 32 32 Cisplatin 40 mg/m2, 1/week
Endostar 30 mg, 1/week
Cisplatin 40 mg/m2, 1/w 3 weeks >3 weeks, or pleural
effusion disappeared
Mao L 2011 [16] 45 45 Cisplatin 40 mg/m2, 1/week
Endostar 30 mg, 2/week
Cisplatin 40 mg/m2, 1/7d 7d/cycle,
2 cycles
>4 cycles, or pleural
effusion disappeared
Li G 2011 [17] 30 30 Bleomycin 60 mg, 1/week
Endostar 30 mg, 1/week
Bleomycin 60 mg, 1/w 3 weeks >3 weeks, or pleural
effusion disappeared
Ma E 2012 [18] 28 28 Cisplatin 40 mg/m2, 1/week
Endostar 30 mg, 1/week
Cisplatin 40 mg/m2, 1/w 4 weeks >4 weeks, or pleural
effusion disappeared
Yao Q 2012 [19] 30 30 Nedaplatin 40 mg, 1/week
Endostar 45 mg, 1/week
Nedaplatin 40 mg, 1/w 4 weeks >4 weeks, or pleural
effusion disappeared
Zheng Q 2013 [20] 60 60 Cisplatin 30–40 mg, d1–3
Endostar 90 mg, d4
Cisplatin 30–40 mg d1–3 21d/cycle,
1–4 cycles
>4 cycles, or pleural
effusion disappeared
Kang Y 2013 [21] 45 45 Cisplatin 40 mg, 2/week
Endostar 30 mg, 2/week
Cisplatin 40 mg, 2/w 3 weeks >3 weeks, or pleural
effusion disappeared
Wen J 2014 [22] 25 29 Lobaplatin 30 mg/m2, d1
Endostar 30 mg, d1
Lobaplatin 30 mg/m2, d1 4 cycles >4 cycles, or pleural
effusion disappeared
Yue G 2014 [23] 43 43 Cisplatin 60 mg, 1/week
Endostar 30 mg, 2/week
Cisplatin 60 mg, 1/w 2–3 weeks >4 weeks, or pleural
effusion disappeared
Tu J [24] 45 45 Cisplatin 40 mg/m2, 2/week
Endostar 45 mg, 2/week
Cisplatin 40 mg/m2, 2/w 3 weeks >3 weeks, or pleural
effusion disappeared
Xu J 2014 [25] 35 35 Nedaplatin 60 mg, 1/week
Endostar 60 mg, 1/week
Nedaplatin 60 mg, 1/w 4 weeks >4 weeks, or pleural
effusion disappeared
Wen X 2015 [26] 68 36 Bleomycin 45 mg, w1
Endostar 45 mg, w2
Bleomycin 45 mg, 1/7d 7d/cycle,
2–4 cycles
>2 weeks, or pleural
effusion disappeared
Hu X 2015 [27] 43 41 Cisplatin 40 mg, 2/week
Endostar 60 mg, 2/week
Cisplatin 40 mg, 2/week 2 weeks >2 weeks, or pleural
effusion disappeared
N numbers of patients, d day, w week
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Table 3 Design quality of included trials








ITT Risk of bias
Liu W 2010 [15] Single center Random number table (SPSS) Clear Clear Yes No Clear No Unclear risk of bias
Mao L 2011 [16] Single center Random number table (SAS) Unclear Unclear Yes No Clear Yes Unclear risk of bias
Li G 2011 [17] Single center Random number table (SAS) sufficient Unclear Yes No Clear Yes Low risk of bias
Ma E 2012 [18] Single center Random number table (SPSS) Unclear Unclear Yes No Clear No Unclear risk of bias
Yao Q 2012 [19] Single center Random number table (SPSS) Unclear Unclear Yes No Clear No Unclear risk of bias
Zheng Q 2013 [20] Single center Random number table (SAS) sufficient Unclear Yes No Clear Yes Low risk of bias
Kang Y 2013 [21] Single center Random number table (SAS) Unclear Unclear Yes N0 Clear Yes Unclear risk of bias
Wen J 2014 [22] Single center unclear Unclear Unclear Yes N0 Clear Yes Unclear risk of bias
Yue G 2014 [23] Single center Random number table (SAS) Unclear Unclear Yes No Clear Yes Unclear risk of bias
Tu J 2014 [24] Single center Random number table (SPSS) Insufficient Unclear Yes No Unclear Yes Low risk of bias
Xu J 2014 [25] Single center Random number table (SPSS) Unclear Clear Yes No Unclear No Unclear risk of bias
Wen X 2015 [26] Single center Random number table (SPSS) Unclear Unclear Yes No Clear No Unclear risk of bias
Hu X 2015 [27] Single center unclear Insufficient Unclear Yes No Clear No Low risk of bias











Fig. 2 Comparison of ORR between Endostar combined with chemotherapeutic agents versus chemotherapeutic agents alone through thoracic
perfusion for treating MPE. ORR, overall response rate; OR, odds ratio; MPE, malignant pleural effusions
Fig. 3 Comparison of DCR between Endostar combined with chemotherapeutic agents versus chemotherapeutic agents alone through thoracic
perfusion for treating MPE. DCR, disease control rate; OR, odds ratio; MPE, malignant pleural effusions
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suggesting that publication bias did not have an impact
on the results (Fig. 7a). The Egger’s test showed that t
value was 0.60 with 12° of freedom (P = 0.562) (Fig. 7b).
Get together, all evidence showed that no publication
biases existed in these included studies. Test for hetero-
geneity of meta-regression showed that Q was 9.548
on 12° of freedom (p = 0.656), and moment-based es-
timate of between studies variance was zero (tau2 of
size of sample = 0; tau2 of ITT = 0), which indicated
that no obvious variation between groups was observed in
this meta-analysis.
Discussion
In clinical work, malignant pleural effusions (MPE) is a
common problem that physicians, oncologists and thor-
acic surgeons often face. Although many malignant tu-
mors directly lead to accumulation of pleural effusions,
the mainly causes for MPE are lung cancer (37.5 %),
breast cancer (16.8 %), and lymphoma (11.5 %). It is re-
ported that 8 to 15 % of lung cancer patients presented
symptom of MPE [30]. The local treatment was primar-
ily current mode of administration for patients with
MPE, including closed thoracic drainage, chemical
Fig. 4 Comparison of QOL between Endostar combined with chemotherapeutic agents versus chemotherapeutic agents alone through thoracic
perfusion for treating MPE. QOL, quality of life; OR, odds ratio; MPE, malignant pleural effusions
Table 4 Comparison of adverse events between Endostar combined with chemotherapeutic agents versus chemotherapeutic
agents alone
Study Myelotoxicity (%) Nausea/vomiting (%) Liver and renal injury (%) Arrhythmia (%) Fever (%)
Group 1 Group 2 Group 1 Group 2 Group 1 Group 2 Group 1 Group 2 Group 1 Group 2
Li G 2011 [17] 4 (13.3) 4 (13.3) 4 (13.3) 3 (10) – – 1 (3.3) 0 (0) 7 (23.3) 6 (20)
Yao Q 2012 [19] 12 (40) 10 (30) 5 (16.7) 5 (16.7) – – – – – –
Zheng Q 2013 [20] 17 (28.3) 16 (26.6) 10 (16.7) 5 (8.3) – – – – – –
Kang Y 2013 [21] 11 (24.4) 10 (22.2) 15 (25) 15 (25) 4 (8.8) 3 (6.6) 2 (3.3) 0 (0) 7 (15.5) 5 (11.1)
Wen J 2014 [22] 22 (73.3) 20 (66.6) 6 (20) 4 (13.3) – – 5 (16.6) 1 (3.3) – –
Yue G 2014 [23] 10 (23.3) 8 (18.6) 7 (16.3) 6 (14) – – – – – –
Tu J 2014 [24] 7 (15.5) 9 (20) 9 (20) 9 (20) 2 (4.4) 2 (4.4) 2 (4.4) 1 (2.2) – –
Xu J 2014 [25] 14 (40) 9 (25.7) 4 (11.4) 2 (5.7) 2 (5.7) 1 (2.8) 1 (2.8) 1 (2.8) 1 (2.8) 0 (0)
Hu X 2015 [27] 7 (16.3) 5 (12.2) 26 (60.4) 20 (48.7) 5 (11.6) 5 (12.1) 3 (6.9) 3 (7.3) 5 (11.6) 5 (12.1)
P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05
Values are given as number of patients (%). Group 1 = Endostar combined with chemotherapeutic agents; Group 2 = chemotherapeutic agents alone
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pleurodesis and thoracic perfusion of antineoplastic
agents such as doxorubicin, carboplatin, cisplatin, mito-
mycin C and 5-fluorouracil [31]. So far, a number of
studies have reported on the advantages and security of
Endostar combined with chemotherapeutic agents versus
chemotherapeutic agents alone through thoracic perfu-
sion for treating MPE. We summed up 13 RCTs and
found that Endostar combined with chemotherapeutic
agents through thoracic perfusion had better ORR and
DCR benefits compared with chemotherapeutic agents
alone (odds ratio = 3.58; 2.97 respectively) for treating
MPE, translating into a 29 and 18 % absolute improve-
ment respectively. These results corroborate that thor-
acic perfusion of Endostar take an active role in
controlling MPE, which indicate that it is a new poten-
tial treatment alternative for treating MPE. Previous
studies have demonstrated that Endostar inhibits endothe-
lial cell migration, represses the neovascularization of new
tumors, blocks the nutrient supply of tumor cells, and
thus suppresses tumor proliferation or metastasis [32]. In
addition, Endostar also could inhibit tumor lymphangio-
genesis and reduce tumor cells into the bloodstream
through the lymphatic [33]. More importantly, Endostar
plays an efficient anti-cancer role in MPE through its sup-
pressive effect on angiogenesis and lymphangiogenesis,
suggesting that Endostar down-regulated the expression
of VEGF-A and VEGF-C, thus inhibit the progression of
MPE [34].
MPE is a common manifestation of disease progression
to patient with advanced lung cancer and other cancers.
In order to control symptoms and improve the quality of
life, careful evaluation of pathology and patient treatment
Fig. 5 Comparison of myelotoxicity and gastrointestinal toxicity between Endostar combined with chemotherapeutic agents versus
chemotherapeutic agents alone through thoracic perfusion for treating MPE. a Comparison of myelotoxicity between Endostar combined with
chemotherapeutic agents versus chemotherapeutic agents alone; b Comparison of gastrointestinal toxicity between Endostar combined with
chemotherapeutic agents versus chemotherapeutic agents alone; OR = odds ratio; MPE, malignant pleural effusions
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individualization is very crucial [2]. In addition to the cure
of the primary disease, the improvement of QOL is im-
portant indicator of disease control, especially to malig-
nant tumors. We all known that most of malignant tumor
can not be cured, but can slow down the progression and
ameliorate symptoms. Our meta-analysis showed that par-
ticipation of Endostar remarkably improved the QOL of
MPE (OR = 3.04, 95 % CI 2.28 to 4.04), which led to an
absolute 29.1 % improvement of the QOL compared to
chemotherapeutic agents alone. Previous study pointed
out that Endostar suppress the VEGF-induced tyrosine
phosphorylation of KDR/Flk-1 (VEGFR-2) as well as the
overall VEGFR-2 expression and the activation of ERK,
p38 MAPK, and AKT in human umbilical vein endothelial
cells, which shows the relationship between Endostar and
VEGF signal pathways and provide a molecular basis for
the antiangiogenic effects of Endostar [12]. Also, Endostar
can exert its anti-tumor effect via suppressing b-FGF-
induced angiogenesis and b-FGF-activated MAPK signal-
ing pathway, suggesting that Endostar might be a useful
agent for treatment of malignant tumors [11].
We found that myelotoxicity and digestive reactions
are most common adverse reactions, but most of which
were grade 1 or 2 and were well tolerated. Through the
further analysis, we noticed that the incidence of myelo-
toxicity, digestive reactions, liver and renal injury,
arrhythmia and fever in treatment of Endostar combin-
ation was as high as that in chemotherapeutic agents
Fig. 6 Comparison of liver and renal injury, arrhythmia and fever between Endostar combined with chemotherapeutic agents versus
chemotherapeutic agents alone through thoracic perfusion for treating MPE. a Comparison of liver and renal injury between Endostar combined
with chemotherapeutic agents versus chemotherapeutic agents alone; b Comparison of arrhythmia between Endostar combined with
chemotherapeutic agents versus chemotherapeutic agents alone; c Comparison of fever between Endostar combined with chemotherapeutic
agents versus chemotherapeutic agents alone; OR = odds ratio; MPE, malignant pleural effusions
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alone, suggesting that the Endostar did not have an extra
impact on the incidence of the AEs. The detection of
heterogeneity is very important to meta-analysis, be-
cause it will affect the pooled statistical efficacy. We
carefully assessed the included studies and found that
those studies had a good clinical homogeneity. More-
over, the Egger’s test and the Begg’s test did not imply
the possibility of publication bias.
However, there are some deficiencies in included trials.
First, most of studies lack adequate analysis of subgroup
data such as age, sex, smoking, histology, and treatment
status and so on. Second, design quality of some is rela-
tively low. Third, sample size of some is too small. The
last, and mostly importantly, most of patients were from
China (because Endostar was approved by the China
State Food and Drug Administration and applied in
treatment of lung cancer), which may lead to geograph-
ical and ethnic differences. In spite of this, these studies
still propose a credible suggestion pointing toward that
the Endostar is effective and safe for treating MPE, and
it is a new choice for treating MPE. Nevertheless, Endo-
star, as a new molecular targeted drug, still needs to be
investigated in the future. Especially, rigorously random-
ized control trials with large sampler size and multi-
centered cooperation should be done before it could be
recommended in clinic extensively.
Fig. 7 Assessment of publication bias. a Egger’s test did not imply a publication biases; b Begg’s test did not show the statistical significance
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Conclusion
Thoracic perfusion of Endostar combined with chemo-
therapeutic agents has a better benefit of ORR and DCR
for treating MPE and improves the QOL of MPE pa-
tients, compared with chemotherapeutic agents alone.
Moreover, the participation of Endostar does not have
an extra influence on the incidence of AEs. However,
rigorously randomized control trials should be required
before it is used widely.
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